Submission of Unaudited Financial Results of the Company for the quarter and Nine Months ended December 31, 2025
3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
3B BlackBio Dx Ltd reported strong consolidated results for Q3 FY26, with revenue from operations at Rs 5,034.73 lakhs, nearly doubling from Rs 2,539.25 lakhs in Q3 FY25 (up ~98%). Nine-month consolidated revenue grew ~44% to Rs 10,648.40 lakhs. Consolidated profit after tax for Q3 stood at Rs 2,244.29 lakhs (up ~66% YoY) and Rs 5,012.50 lakhs for nine months (up ~26% YoY). Standalone results were more modest — Q3 revenue Rs 2,437.62 lakhs (up ~4%) and PAT Rs 1,446.02 lakhs (up ~7.5%). Growth is driven primarily by the Diagnostic Kits segment (Rs 4,867.50 lakhs in Q3 vs Rs 2,328.30 lakhs) following the recent acquisition of Coris Holding SRL (Belgium), which contributed Rs 2,400.70 lakhs in sales and Rs 700.10 lakhs in profit during the quarter. Agrochemical business declined YoY. Q3 other expenses include CE IVDR regulatory and conference costs; H1 also had Rs 138.60 lakhs of M&A expenses. Auditor (Baheti & Co.) issued an unqualified limited review report.
Positive for shareholders — strong revenue and profit growth at consolidated level driven by the diagnostics business and Coris acquisition. Standalone growth is muted but profitability remains high. Watch for margin trends as new acquisitions integrate and regulatory expenses continue.